Key Points
- Ra Capital Management, Hemab Therapeutics’ major shareholder, bought 39,869 shares on May 11 for about $989,150 at an average price of $24.81 per share.
- The purchase lifted Ra Capital’s direct holdings to 6,365,783 shares, valued at roughly $157.9 million, and represented a 0.63% increase in its position.
- Ra Capital has been actively buying the stock in recent days, including a much larger 2.675 million-share purchase on May 4 at $18.00 per share; meanwhile, Wall Street Zen upgraded Hemab Therapeutics to a hold rating.
Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG - Get Free Report) major shareholder Ra Capital Management, L.P. bought 1,483 shares of the business's stock in a transaction that occurred on Friday, May 8th. The shares were bought at an average price of $24.98 per share, with a total value of $37,045.34. Following the transaction, the insider directly owned 6,325,914 shares in the company, valued at $158,021,331.72. This trade represents a 0.02% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.
Ra Capital Management, L.P. also recently made the following trade(s):
- On Monday, May 11th, Ra Capital Management, L.P. bought 39,869 shares of Hemab Therapeutics stock. The shares were bought at an average price of $24.81 per share, with a total value of $989,149.89.
- On Thursday, May 7th, Ra Capital Management, L.P. bought 9,906 shares of Hemab Therapeutics stock. The shares were bought at an average price of $24.46 per share, with a total value of $242,300.76.
- On Wednesday, May 6th, Ra Capital Management, L.P. bought 68,018 shares of Hemab Therapeutics stock. The shares were bought at an average price of $24.60 per share, with a total value of $1,673,242.80.
- On Tuesday, May 5th, Ra Capital Management, L.P. bought 97,411 shares of Hemab Therapeutics stock. The shares were bought at an average price of $24.63 per share, with a total value of $2,399,232.93.
- On Monday, May 4th, Ra Capital Management, L.P. bought 2,675,000 shares of Hemab Therapeutics stock. The shares were bought at an average price of $18.00 per share, with a total value of $48,150,000.00.
Hemab Therapeutics Trading Down 0.5%
Hemab Therapeutics stock opened at $25.00 on Tuesday. Hemab Therapeutics Holdings, Inc. has a one year low of $23.00 and a one year high of $36.61.
Wall Street Analysts Forecast Growth
Separately, Wall Street Zen upgraded Hemab Therapeutics to a "hold" rating in a research report on Saturday.
Check Out Our Latest Stock Report on Hemab Therapeutics
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
